Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Vaccines

HHS Pulls Funding for GeoVax’s Next-Gen COVID-19 Vaccine

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb development.

April 17, 2025

2 min read

Tristan Manalac

Entrance to the U.S. Department of Health and Human Services in Washington, DC

Government

Trump Eyes $40 Billion Budget Cut for HHS: Reports

Despite these cuts, the FDA should be able to stay above a “trigger” level that would prevent it from collecting fees from the pharma industry and deprive it of approximately half of its annual funding, according to The Washington Post.

April 17, 2025

2 min read

Tristan Manalac

Policy

RFK Jr. Eyes Changes to Vaccines Injury Surveillance System to Deduce ‘Culprit’

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to an unstated problem. The reporting system is at the heart of the departure of CBER head Peter Marks.

April 17, 2025

2 min read

Tristan Manalac

Illustration of employee replacement concept with one employee leaving and another trying to get a job

Layoffs

Q1 Biopharma Layoffs Hit California, Massachusetts Hard

During the first quarter, 22 rounds of biopharma layoffs in California affected about 995 employees total, while 17 rounds in Massachusetts impacted around 410 people, based on BioSpace estimates. Meanwhile, competition for jobs in those states increased year over year, according to BioSpace data.

April 17, 2025

5 min read

Angela Gabriel

Photo of Boston, Massachusetts, at the Boston Harbor and Financial District with a mix of contemporary and historic architecture.

Job Trends

9 Companies Hiring in Massachusetts

Looking for a biopharma job in Massachusetts? Check out the BioSpace list of nine companies hiring life sciences professionals like you.

April 17, 2025

2 min read

Angela Gabriel

Diverse cultures, international communication concept. Human silhouette with speech bubbles.

Regulatory

Former FDA Officials Sound Alarm: Visible Changes May Be ‘Tip of the Iceberg’

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER director spoke to analysts about potential implications for drug review timelines and agency morale.

April 16, 2025

3 min read

Heather McKenzie

Find understanding between people. Reach your opponent. Building a bridge of understanding and reasoning. Discover common ground. Pave way for cooperation or peaceful disagreement. Resolving conflict

Mergers & acquisitions

Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer

Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.

April 16, 2025

1 min read

Dan Samorodnitsky

Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.

Clinical research

Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

April 16, 2025

2 min read

Tristan Manalac